To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min An Austin startup that has been ...
Following successful small-animal trials that confirmed bioequivalence, BioNxt is now taking the final preclinical step to prepare its sublingual Cladribine formulation for human testing. The upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results